Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

@article{Hugh2009BreastCS,
  title={Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.},
  author={Judith Hugh and Jonathan C. Hanson and Maggie Chon U. Cheang and Torsten O. Nielsen and Charles M. Perou and Charles Dumontet and John M Reed and Maryla Krajewska and Isabelle 6 Treilleux and Matthieu Rupin and Emmanuelle Magherini and John Mackey and Miguel Mart{\'i}n and C. Vogel},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 8},
  pages={
          1168-76
        }
}
PURPOSE To investigate the prognostic and predictive significance of subtyping node-positive early breast cancer by immunohistochemistry in a clinical trial of a docetaxel-containing regimen. METHODS Pathologic data from a central laboratory were available for 1,350 patients (91%) from the BCIRG 001 trial of docetaxel, doxorubicin, and cyclophosphamide (TAC) versus fluorouracil, doxorubicin, and cyclophosphamide (FAC) for operable node-positive breast cancer. Patients were classified by tumor… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 282 CITATIONS

FILTER CITATIONS BY YEAR

2009
2019

CITATION STATISTICS

  • 14 Highly Influenced Citations

  • Averaged 15 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 51 REFERENCES

Clinical application of the 70-gene profile: The MINDACT trial

  • F Cardoso, L Van’t Veer, E Rutgers
  • J Clin Oncol 26:729-735,
  • 2008

Similar Papers

Loading similar papers…